Search

BackgroundThe coronavirus disease (COVID-19) pandemic, caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has resulted in the self-quarantine of countless people due to possible infection. This situation makes telemedicine necessary as it can overcome geographical barriers, increase the number of people served, and provide online clinical support for patients. However, the outcomes of telemedicine have not yet been evaluated. ObjectiveThe aim of our study is to describe the epidemiological features and clinical symptoms of patients receiving remote diagnosis and treatment at the online outpatient clinic of our hospital, as well as to analyze the outcomes and advantages of telemedicine, during the COVID-19 pandemic. MethodsData from patients receiving remote diagnosis and treatment via consultation services for COVID-19 concerns at the online outpatient clinic of Henan Provincial People's Hospital from January 24 to February 17, 2020, were collected. A retrospective analysis was performed on epidemiological features, clinical symptoms, and preliminary outcomes. ResultsOnline inquiry, consultation, and suggestions were provided for patient concerns related to COVID-19. Our hospital also offered offline noncontact drug delivery services following online ordering and payment. A total of 4589 patients receiving remote diagnosis and treatment were recruited. The daily number of online outpatient visits initially increased and then decreased, reaching its peak on January 28 when the daily number of online outpatient visits totaled 612. Of 4589 patients, 1940 (42.3%) were males and 2649 (57.7%) were females (age range: 78 days to 85 years). Most patients were aged 20-39 years (n=3714, 80.9%) and came from Henan Province (n=3898, 84.9%). The number of patients from other provinces was 691 (15.1%). During the online consultations, patients discussed the following symptoms: fever (n=2383), cough (n=1740), nasal obstruction (n=794), fatigue (n=503), and diarrhea (n=276). A total of 873 orders of noncontact drug delivery following online payment was completed. The daily number of such orders gradually stabilized after the initial, steady increase. For offline drug delivery orders, the median (IQR) was 36 (58). An online satisfaction survey was filled out postconsultation by patients; of the 985 responses received, 98.1% (n=966) of respondents were satisfied with the service they received. ConclusionsRemote diagnosis and treatment offered via online outpatient consultations effectively reduced the burden on hospitals, prevented overcrowding, reduced the risk of cross-infection, and relieved patients' anxiety during the COVID-19 outbreak. This plays an essential role in pandemic management.

Globally, the rollout of COVID‐19 vaccine had been faced with a significant barrier in the form of vaccine hesitancy. This study adopts a multi‐stage perspective to explore the prevalence and determinants of COVID‐19 vaccine hesitancy, focusing on their dynamic evolutionary features. Guided by the integrated framework of the 3Cs model (complacency, confidence, and convenience) and the EAH model (environmental, agent, and host), this study conducted three repeated national cross‐sectional surveys. These surveys carried out from July 2021 to February 2023 across mainland China, targeted individuals aged 18 and older. They were strategically timed to coincide with three critical vaccination phases: universal coverage (stage 1), partial coverage (stage 2), and key population coverage (stage 3). From 2021 to 2023, the surveys examined sample sizes of 29 925, 6659, and 5407, respectively. The COVID‐19 vaccine hesitation rates increased from 8.39% in 2021 to 29.72% in 2023. Urban residency, chronic condition, and low trust in vaccine developer contributed to significant COVID‐19 vaccine hesitancy across the pandemic. Negative correlations between the intensity of vaccination policies and vaccine hesitancy, and positive correlations between vaccine hesitancy and long COVID, were confirmed. This study provides insights for designing future effective vaccination programs for emerging vaccine‐preventable infectious X diseases. [ABSTRACT FROM AUTHOR]

Aims and Objectives: To investigate whether chronic diseases are associated with higher COVID‐19 vaccine hesitancy and explore factors that influence COVID‐19 vaccine hesitancy in patients with chronic diseases. Background: Vaccine hesitancy has been acknowledged as one of the greatest hazards to public health. However, little information is available about COVID‐19 vaccine hesitancy among patients with chronic diseases who may be more susceptible to COVID‐19 infection, severe disease or death. Methods: From 6 to 9 August 2021, we performed an internet‐based cross‐sectional survey with 22,954 participants (14.78% participants with chronic diseases). Propensity score matching with 1:1 nearest neighbourhood was used to reduce confounding factors between patients with chronic diseases and the general population. Using a multivariable logistic regression model, the factors impacting COVID‐19 vaccine hesitancy were identified among patients with chronic diseases. Results: Both before and after propensity score matching, patients with chronic diseases had higher COVID‐19 vaccine hesitancy than the general population. In addition, self‐reported poor health, multiple chronic diseases, lower sociodemographic backgrounds and lower trust in nurses and doctors were associated with COVID‐19 vaccine hesitancy among patients with chronic diseases. Conclusions: Patients with chronic diseases were more hesitant about the COVID‐19 vaccine. Nurses should focus on patients with chronic diseases with poor health conditions, low socioeconomic backgrounds and low trust in the healthcare system. Relevance to Clinical Practice: Clinical nurses are recommended to not only pay more attention to the health status and sociodemographic characteristics of patients with chronic diseases but also build trust between nurses and patients by improving service levels and professional capabilities in clinical practice. Patient or Public Contribution: Patients or the public were not involved in setting the research question, the outcome measures, or the design or implementation of the study. However, all participants were invited to complete the digital informed consent and questionnaires. [ABSTRACT FROM AUTHOR]

Background: The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has resulted in an ongoing global pandemic of coronavirus disease 2019 (COVID-19). The challenges associated with imaging infected patients have resulted, to date, in a paucity of metabolic imaging studies of patients with severe COVID-19 infection. Furthermore, it remains unclear if any abnormal metabolic events are taking place in patients who have recovered from COVID-19. Purpose: To use [18F] fluorodeoxyglucose ([18F] FDG) positron emission tomography/computed tomography (PET/CT) to measure metabolic activity in inflamed organs of patients convalescing post severe COVID-19 infection. Materials and methods: A prospective study was performed in seven convalescing patients who were recovering from severe COVID-19 infection in February 2020. Prior to [18F] FDG PET/CT, all patients had received two consecutive negative results of real-time reverse transcriptase polymerase chain reaction (RT-PCR) for SARS-CoV-2 nucleic acid. Clinical intake including symptoms, treatment, laboratory test results, and follow-up was performed. The PET/CT images of COVID-19 patients were compared to a control group of patients that were matched for age and sex. Results: Residual pulmonary lesions were present in all patients and maximum standard uptake value (SUVmax), average standard uptake value (SUVavg), maximum CT intensity (CTmax), and average CT intensity (CTavg) were all significantly greater than in the control group (p < 0.01 for all). In addition, SUVmax and SUVavg were significantly greater in the mediastinal lymph node and liver, and SUVmax was significantly greater in the spleen, of COVID-19 patients compared with controls (p < 0.05 for all). For the spleen, SUVmax (r2 = 0.863, p = 0.003) and SUVavg (r2 = 0.797, p = 0.007) were significantly correlated with blood lymphocyte count, and which was below the normal range in five of the seven (71.4%) patients convalescing post severe COVID-19 infection. Conclusion: [18F] FDG PET/CT quantitative analysis has shown that significant inflammation remained in lungs, mediastinal lymph nodes, spleen, and liver after two consecutive negative RT-PCR tests in patients convalescing post severe COVID-19 infection. [ABSTRACT FROM AUTHOR]

β-NaYF4:Yb,Er nanoparticles (NPs) are one of the most efficient upconversion materials, which can convert near-infrared light to higher-energy light through multiple photon absorptions or energy transfer. In addition, they may be attractive alternative donors for luminescence resonance energy transfer (LRET) studies, because of their sharp absorption and emission profiles, high quantum yields, large anti-stokes shifts, long lifetime, low toxicity, and superior photo-stability. In principle, many problems of fluorescence resonance energy transfer (FRET), such as excitation of acceptors, emission overlaps between donors and acceptors, high background noise, potential toxicity, and instability, can be overcome using β-NaYF4:Yb,Er NPs as energy donors. Because the organic coating induced separation can significantly reduce the energy transfer efficiency and aqueous FRET system is difficult to be applied in devices, we demonstrate a novel NP-dye LRET system in solid state. The emission of the β-NaYF4:Yb,Er NPs at 539 nm overlaps with the absorption of the tetrametrylrhodarnine isothiocyante (TRITC), satisfying the requirement of LRET process. Since TRITC molecules are adsorbed on the β-NaYF4:Yb,Er NPs by an electrostatic interaction, the interaction distance is suitable for LRET without any further modulation. The resultant solid LRET system is ready for the further applications for devices. [ABSTRACT FROM AUTHOR]